Lupin Ltd Announces Q2 and H1 Results for FY2025-26, Reveals Exceptional Items and Dividend Disbursement

Lupin Ltd, a prominent pharmaceutical company, has announced its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. The company's revenue from operations stands at INR 58,054.1 million for H1 FY2025-26. The Board approved an exceptional item involving the transfer of OTC and API R&D business in India to its subsidiaries, resulting in a gain of INR 6,589.6 million. The company also determined a diminution in the value of investment in a subsidiary, resulting in a provision of INR 700.0 million. Additionally, Lupin disbursed a final dividend of INR 12/- per equity share. The company has also provided for an ongoing dispute of INR 858.1 million.